Please assess the completion status of the following clinical trial:

Trial Title: Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally Advanced Pancreatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Pathologically confirmed adenocarcinoma or poorly differentiated carcinoma of the pancreas, ampulla of Vater, or distal bile duct~  * Locally advanced disease~ * Medically inoperable, unresectable, or borderline resectable disease~    * No previously resected disease (i.e., status post-pancreaticoduodenotomy)~* No non-adenocarcinoma, adenosquamous carcinoma, islet cell carcinoma, cyst adenoma, cystadenocarcinoma, carcinoid tumor, or duodenal carcinoma~* No lesions in the tail of the pancreas and/or splenic artery/vein involvement/encasement~* No recurrent or metastatic (M1) disease~PATIENT CHARACTERISTICS:~* Karnofsky performance status 60-100%~* WBC \> 3,000/μL~* Platelet count \> 100,000/μL~* Bilirubin ≤ 2 mg/dL~* SGOT \< 5 times upper limit of normal (ULN)~* Creatinine \< 1.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Adequate oral nutrition (e.g., ≥ 1,500 calories/day, stable weight for ≥ 2 weeks, and ≤ 5% weight loss)~* No active malignancy within the past 3 years, except cervical carcinoma in situ or nonmelanoma skin cancer that has been removed~* No severe, active comorbidity, including any of the following:~  * Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months~ * Transmural myocardial infarction within the past 6 months~ * Acute bacterial or fungal infection requiring IV antibiotics at the time of study registration~ * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within the past month or precluding study therapy at the time of study registration~ * Active hepatitis, decompensated cirrhosis, or clinically significant liver failure~ * Other severe comorbid condition, as determined by the principal investigator~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* No prior chemotherapy~* No prior radiotherapy to any upper abdominal site~* No concurrent prophylactic colony-stimulating factors during radiotherapy~* No concurrent warfarin~* No other concurrent chemotherapy, immunotherapy, hormonal cancer therapy, radiotherapy, surgery for cancer, or experimental therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Radiotherapy plus gemcitabine (Type: EXPERIMENTAL): Drug: gemcitabine hydrochloride~Radiation: intensity-modulated radiation therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).